Osimertinib in adjuvant treatment EGFR+ non‑small cell lung cancer – ADAURA trial
MUDr. Ondřej Bílek
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Approximately one-quarter of patients with non-small cell lung cancer are diagnosed with early or locally advanced stage of the disease suitable for surgery. There is a high risk of disease recurrence after adjuvant chemotherapy. The ADAURA trial demonstrated a significant benefit of adjuvant treatment with osimertinib in patients with non-small cell lung cancer with evidence of aberration of EGFR del19 or L858R in exon 21.
Non-small cell lung cancer, EGFR, osimertinib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...